UY33959A - INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7 - Google Patents
INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7Info
- Publication number
- UY33959A UY33959A UY0001033959A UY33959A UY33959A UY 33959 A UY33959 A UY 33959A UY 0001033959 A UY0001033959 A UY 0001033959A UY 33959 A UY33959 A UY 33959A UY 33959 A UY33959 A UY 33959A
- Authority
- UY
- Uruguay
- Prior art keywords
- powerful
- selective inhibitors
- inhibitors
- selective
- escanea
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Insects & Arthropods (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describe una composición de la materia, la cual comprende un polipéptido aislado, el cual es un inhibidor de NaV1.7 restringido periféricamente. En algunas realizaciones que se dan a conocer, el polipéptido aislado es un inhibidor de NaV1.7 y/o NaV1.3. Otras realizaciones son realizaciones conjugadas de la composición de la materia de la invención y composiciones farmacéuticas que contienen la composición de la materia de la invención. Se dan a conocer ácidos nucleicos aislados que codifican algunas realizaciones de polipéptidos y vectores de expresión de la invención, así como células huésped recombinantes que los contienen. También se da a conocer un método para tratar o prevenir el dolor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161453492P | 2011-03-16 | 2011-03-16 | |
US201261608088P | 2012-03-07 | 2012-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33959A true UY33959A (es) | 2012-09-28 |
Family
ID=45895479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033959A UY33959A (es) | 2011-03-16 | 2012-03-16 | INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7 |
Country Status (23)
Country | Link |
---|---|
US (2) | US9340590B2 (es) |
EP (1) | EP2686340A2 (es) |
JP (2) | JP2014509859A (es) |
KR (1) | KR20140145947A (es) |
CN (1) | CN103930437A (es) |
AP (1) | AP2013007173A0 (es) |
AR (1) | AR088413A1 (es) |
AU (1) | AU2012228990B2 (es) |
BR (1) | BR112013023674A2 (es) |
CA (1) | CA2830065A1 (es) |
CL (1) | CL2013002673A1 (es) |
CO (1) | CO6821886A2 (es) |
CR (1) | CR20130533A (es) |
EA (1) | EA201391331A1 (es) |
HK (1) | HK1198173A1 (es) |
MA (1) | MA35385B1 (es) |
MX (1) | MX2013010497A (es) |
PE (1) | PE20140593A1 (es) |
SG (2) | SG193434A1 (es) |
TW (1) | TW201300407A (es) |
UY (1) | UY33959A (es) |
WO (1) | WO2012125973A2 (es) |
ZA (1) | ZA201306920B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR096927A1 (es) | 2013-03-12 | 2016-02-10 | Amgen Inc | INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7 |
EP2970408B1 (en) | 2013-03-12 | 2018-01-10 | Amgen Inc. | Potent and selective inhibitors of nav1.7 |
EP2968495B1 (en) * | 2013-03-15 | 2019-07-03 | Daniel J. Capon | Hybrid immunoglobulin containing non-peptidyl linkage |
EP3116486B1 (en) | 2014-03-14 | 2019-12-04 | Daniel J. Capon | Hybrid immunoglobulin containing non-peptidyl linkage |
CN105348392B (zh) * | 2015-11-18 | 2019-08-02 | 北京华金瑞清生物医药技术有限公司 | 一种Nav1.7抑制剂及其改造方法 |
WO2017147147A1 (en) * | 2016-02-23 | 2017-08-31 | PixarBio Corporation | Compositions comprising nav1.7 selective inhibitors for treating acute, post-operative, or chronic pain and methods of using the same |
EP3512870B1 (en) * | 2016-09-16 | 2022-08-03 | Olipass Corporation | Scn9a antisense oligonucleotides |
IL267881B2 (en) * | 2017-01-24 | 2024-03-01 | Olipass Corp | SCN9A antisense painkiller |
CN109517041B (zh) * | 2018-11-14 | 2019-09-17 | 青海芬陀利华生物科技有限公司 | Gptx-1毒素及其应用 |
US20230374084A1 (en) | 2020-09-23 | 2023-11-23 | Aldevron, Llc | Potent and selective inhibitors of nav1.7 |
CN113429463B (zh) * | 2021-05-18 | 2022-08-23 | 湖南百尔泰克生物医药有限公司 | 一种具有镇痛作用的多肽及其应用 |
WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
TW202408501A (zh) | 2022-04-22 | 2024-03-01 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4351337A (en) | 1973-05-17 | 1982-09-28 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4083368A (en) | 1976-09-01 | 1978-04-11 | Freezer Winthrop J | Inhaler |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US5002936A (en) | 1985-04-12 | 1991-03-26 | Seymour Lieberman | Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
AU610083B2 (en) | 1986-08-18 | 1991-05-16 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
AU607172B2 (en) | 1986-12-22 | 1991-02-28 | Cygnus, Inc. | Diffusion matrix for transdermal drug administration |
US4906169A (en) | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US5023084A (en) | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US4983395A (en) | 1987-11-12 | 1991-01-08 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US4849224A (en) | 1987-11-12 | 1989-07-18 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
WO1990001063A1 (en) | 1988-07-23 | 1990-02-08 | Delta Biotechnology Limited | New secretory leader sequences |
US4925677A (en) | 1988-08-31 | 1990-05-15 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5171264A (en) | 1990-02-28 | 1992-12-15 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
JP3693671B2 (ja) | 1991-03-15 | 2005-09-07 | アムゲン インコーポレーテッド | ポリペプチドのpeg化 |
CA2082951C (en) | 1991-03-15 | 1999-12-21 | Robert M. Platz | Pulmonary administration of granulocyte colony stimulating factor |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
JPH0640945A (ja) | 1992-07-23 | 1994-02-15 | Kureha Chem Ind Co Ltd | Fcフラグメント結合抗腫瘍剤 |
WO1994008599A1 (en) | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
US5432155A (en) | 1993-06-29 | 1995-07-11 | The Salk Institute For Biological Studies | Conotoxins I |
US5514774A (en) | 1993-06-29 | 1996-05-07 | University Of Utah Research Foundation | Conotoxin peptides |
US5460820B1 (en) | 1993-08-03 | 1999-08-03 | Theratech Inc | Method for providing testosterone and optionally estrogen replacement therapy to women |
US6342225B1 (en) | 1993-08-13 | 2002-01-29 | Deutshces Wollforschungsinstitut | Pharmaceutical active conjugates |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
AU1843295A (en) | 1994-02-23 | 1995-09-11 | Chiron Corporation | Method and compositions for increasing the serum half-life of pharmacologically active agents |
FR2717688B1 (fr) | 1994-03-28 | 1996-07-05 | Lhd Lab Hygiene Dietetique | Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA. |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
CN1170360A (zh) | 1994-12-21 | 1998-01-14 | 瑟垃技术有限公司 | 具有粘性贴面和剥离密封圆片的经皮输送*** |
MY131733A (en) | 1994-12-22 | 2007-08-30 | Astra Ab | Aerosol drug formulations |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5776896A (en) | 1996-01-03 | 1998-07-07 | Zeneca Limited | Analgesic peptides from venom of grammostola spatulata and use thereof |
US5756663A (en) | 1996-01-03 | 1998-05-26 | Zeneca Limited | Antiarrhythmic peptide from venom of spider Grammostola spatulata |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US5783208A (en) | 1996-07-19 | 1998-07-21 | Theratech, Inc. | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
AU5369798A (en) | 1996-11-27 | 1998-06-22 | Bachem Bioscience, Inc. | Shk toxin compositions and methods of use |
ATE307829T1 (de) | 1996-12-26 | 2005-11-15 | Suntory Ltd | Skorpion-spezifische neuropeptide |
US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
JP3530004B2 (ja) | 1998-02-06 | 2004-05-24 | 株式会社日立ユニシアオートモティブ | 吸入式投薬器 |
US6022952A (en) | 1998-04-01 | 2000-02-08 | University Of Alberta | Compositions and methods for protein secretion |
US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
AUPP589598A0 (en) | 1998-09-14 | 1998-10-08 | University Of Queensland, The | Novel peptides |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
JP4475814B2 (ja) | 1998-11-20 | 2010-06-09 | 扶桑薬品工業株式会社 | タンパク質発現ベクターとその使用 |
AU769610B2 (en) | 1998-12-23 | 2004-01-29 | Amgen, Inc. | Polyol/oil suspensions for the sustained release of proteins |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
CA2368068A1 (en) | 1999-03-18 | 2000-09-21 | Steven M. Ruben | 27 human secreted proteins |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
CA2394229C (en) | 1999-11-26 | 2010-04-13 | Mcgill University | Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy |
WO2001054472A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
SE0000935D0 (sv) | 2000-03-21 | 2000-03-21 | Astrazeneca Ab | An inhalation device |
US7125847B1 (en) | 2000-04-07 | 2006-10-24 | The Research Foundation Of State University Of New York At Buffalo | Mechanically activated channel blocker |
CN1133461C (zh) | 2000-04-11 | 2004-01-07 | 厦门北大之路生物工程有限公司 | 虎纹捕鸟蜘蛛毒素提取物在制备镇痛药物中的应用 |
AU2001259063A1 (en) | 2000-04-12 | 2001-10-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1280895B1 (en) | 2000-05-10 | 2005-08-03 | Centre National De La Recherche Scientifique (Cnrs) | Polypeptide inhibiting a proton-gated na+ channel |
EP1177806A1 (en) | 2000-08-04 | 2002-02-06 | The Technology Partnership Public Limited Company | Dry powder inhaler |
GB0021617D0 (en) | 2000-09-02 | 2000-10-18 | Imp College Innovations Ltd | Diagnosis and treatment of cancer |
JP5013152B2 (ja) | 2001-02-28 | 2012-08-29 | 株式会社ビーエムジー | 蛋白質複合体形成剤 |
JP4336771B2 (ja) | 2001-03-09 | 2009-09-30 | モルフォシス アーゲー | 血清アルブミン結合部分 |
US20050054051A1 (en) | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
ATE527375T1 (de) | 2001-04-12 | 2011-10-15 | Imp Innovations Ltd | Diagnose und behandlung von brustkrebs mit scn5a |
GB0120238D0 (en) | 2001-08-20 | 2001-10-10 | Univ College Of London | Sodium channel regulators and modulators |
WO2003034988A2 (en) | 2001-10-19 | 2003-05-01 | Idexx Laboratories, Inc. | Injectable compositions for the controlled delivery of pharmacologically active compound |
US6900317B2 (en) | 2002-02-19 | 2005-05-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them |
US7125676B2 (en) | 2002-02-25 | 2006-10-24 | Vanderbilt University | Expression system for human brain-specific voltage-gated sodium channel, type 1 |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
EP2226316B1 (en) | 2002-05-30 | 2016-01-13 | The Scripps Research Institute | Copper-catalysed ligation of azides and acetylenes |
GB0219512D0 (en) | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Inhalation compositions with high drug ratios |
JP4488522B2 (ja) | 2003-03-26 | 2010-06-23 | 株式会社ファルマデザイン | イオンチャネルの活性を阻害する低分子ペプチド |
ES2298785T3 (es) | 2003-06-12 | 2008-05-16 | Eli Lilly And Company | Proteinas de fusion. |
PE20050355A1 (es) | 2003-08-05 | 2005-05-16 | Vertex Pharma | Composiciones referidas a inhibidores de canales ionicos regulados por voltaje |
US7615563B2 (en) | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
AU2004263179B8 (en) | 2003-08-08 | 2011-07-14 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
US7125908B2 (en) | 2003-08-29 | 2006-10-24 | Allergan, Inc. | Treating pain using selective antagonists of persistent sodium current |
US7060723B2 (en) | 2003-08-29 | 2006-06-13 | Allergan, Inc. | Treating neurological disorders using selective antagonists of persistent sodium current |
WO2005069969A2 (en) | 2004-01-21 | 2005-08-04 | University Of Utah Research Foundation | Mutant sodium channel nav1.7 and methods related thereto |
WO2005118614A1 (en) | 2004-04-08 | 2005-12-15 | Avigen, Inc. | Methods and compositions for treating neuropathic pain |
WO2005105057A1 (en) | 2004-04-23 | 2005-11-10 | Amgen Inc. | Sustained release formulations |
WO2006000116A1 (de) | 2004-06-23 | 2006-01-05 | Huber+Suhner Ag | Breitband-patchantenne |
GB0414272D0 (en) | 2004-06-25 | 2004-07-28 | Cellpep Sa | OsK1 derivatives |
US7259145B2 (en) | 2004-07-07 | 2007-08-21 | The Research Foundation Of State University Of New York | Mechanically activated channel blocker |
CA2580796C (en) | 2004-09-24 | 2013-03-26 | Amgen Inc. | Modified fc molecules having peptides inserted in internal loop regions |
EP2474316B1 (en) | 2004-10-07 | 2016-04-06 | The Regents of The University of California | Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels |
JP2008519034A (ja) | 2004-11-03 | 2008-06-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネル調節剤としてのピリミジン誘導体および使用方法 |
US20060199812A1 (en) | 2005-01-24 | 2006-09-07 | Amgen Inc. | Method of conjugating aminothiol containing molecules to vehicles |
US7531523B2 (en) | 2005-02-17 | 2009-05-12 | Vertex Pharmaceuticals Incorporated | Sodium channel protein type III alpha-subunit splice variant |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
GB0517487D0 (en) | 2005-08-26 | 2005-10-05 | Isis Innovation | Antibodies |
US7972813B2 (en) | 2005-09-30 | 2011-07-05 | Vertex Pharmaceuticals Incorporated | Tetrodotoxin-resistant sodium channel alpha subunit |
EP1948685B1 (en) | 2005-11-08 | 2018-04-18 | Activen Sa | Mu-conotoxin peptides and use thereof as a local anesthetic |
WO2007109324A2 (en) * | 2006-03-21 | 2007-09-27 | Xenon Pharmaceuticals, Inc. | Potent and selective nav 1.7 sodium channel blockers |
JP4742345B2 (ja) * | 2006-06-20 | 2011-08-10 | 独立行政法人産業技術総合研究所 | カルシウムチャネルを遮断するグラモストラ・スパチュラタ由来のポリペプチドおよびその遺伝子 |
EP2089426B1 (en) | 2006-06-20 | 2016-04-20 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Antimicrobial kinocidin compositions and methods of use |
US7825093B2 (en) * | 2006-10-25 | 2010-11-02 | Amgen Inc. | Methods of using OSK1 peptide analogs |
US8183221B2 (en) | 2007-09-05 | 2012-05-22 | Medtronic, Inc. | Suppression of SCN9A gene expression and/or function for the treatment of pain |
CN101480393A (zh) * | 2008-01-07 | 2009-07-15 | 云南昊邦制药有限公司 | 草乌甲素作为制备治疗Nav1.7疼痛病症药物的应用 |
WO2009097530A2 (en) | 2008-01-30 | 2009-08-06 | Baylor College Of Medicine | Peptides that target dorsal root ganglion neurons |
US20110312533A1 (en) | 2009-02-02 | 2011-12-22 | Chromocell Corporation | CELL LINES EXPRESSING NaV AND METHODS OF USING THEM |
WO2010104115A1 (ja) * | 2009-03-10 | 2010-09-16 | 独立行政法人産業技術総合研究所 | 膜タンパク質を特異的に認識するポリペプチドの調製方法 |
WO2010104114A1 (ja) | 2009-03-10 | 2010-09-16 | 独立行政法人産業技術総合研究所 | ポリペプチドライブラリーを調製する方法 |
EP3385279B1 (en) | 2009-03-20 | 2020-02-26 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
CN102573884B (zh) * | 2009-09-15 | 2015-01-14 | 阿洛莫恩临床有限公司 | 从蜘蛛毒液中分离的新型肽及其应用 |
GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
CA2778673A1 (en) | 2009-10-27 | 2011-05-05 | Karen Margrete Miller | Function modifying nav 1.7 antibodies |
US8871996B2 (en) | 2010-06-09 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing human voltage-gated sodium channels |
US9279003B2 (en) | 2010-07-07 | 2016-03-08 | Purdue Pharma L.P. | Analogs of sodium channel peptide toxin |
CA2873860A1 (en) | 2012-05-18 | 2013-11-21 | Janssen Biotech, Inc. | Huwentoxin-iv variants and methods of use |
-
2012
- 2012-03-16 KR KR1020137027301A patent/KR20140145947A/ko not_active Application Discontinuation
- 2012-03-16 US US14/005,135 patent/US9340590B2/en active Active
- 2012-03-16 WO PCT/US2012/029537 patent/WO2012125973A2/en active Application Filing
- 2012-03-16 CN CN201280023655.XA patent/CN103930437A/zh active Pending
- 2012-03-16 BR BR112013023674A patent/BR112013023674A2/pt not_active IP Right Cessation
- 2012-03-16 SG SG2013068770A patent/SG193434A1/en unknown
- 2012-03-16 EP EP12711312.4A patent/EP2686340A2/en not_active Withdrawn
- 2012-03-16 MX MX2013010497A patent/MX2013010497A/es unknown
- 2012-03-16 UY UY0001033959A patent/UY33959A/es not_active Application Discontinuation
- 2012-03-16 JP JP2013558223A patent/JP2014509859A/ja active Pending
- 2012-03-16 CA CA2830065A patent/CA2830065A1/en not_active Abandoned
- 2012-03-16 TW TW101109226A patent/TW201300407A/zh unknown
- 2012-03-16 EA EA201391331A patent/EA201391331A1/ru unknown
- 2012-03-16 PE PE2013002050A patent/PE20140593A1/es not_active Application Discontinuation
- 2012-03-16 AP AP2013007173A patent/AP2013007173A0/xx unknown
- 2012-03-16 SG SG10201601789TA patent/SG10201601789TA/en unknown
- 2012-03-16 AU AU2012228990A patent/AU2012228990B2/en active Active
- 2012-03-19 AR ARP120100896A patent/AR088413A1/es unknown
-
2013
- 2013-09-13 ZA ZA2013/06920A patent/ZA201306920B/en unknown
- 2013-09-16 CL CL2013002673A patent/CL2013002673A1/es unknown
- 2013-10-08 MA MA36308A patent/MA35385B1/fr unknown
- 2013-10-11 CO CO13242679A patent/CO6821886A2/es unknown
- 2013-10-16 CR CR20130533A patent/CR20130533A/es unknown
-
2014
- 2014-11-21 HK HK14111760.9A patent/HK1198173A1/xx unknown
-
2016
- 2016-04-20 US US15/134,305 patent/US9796766B2/en active Active
- 2016-08-22 JP JP2016161682A patent/JP2017031157A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MA35385B1 (fr) | 2014-09-01 |
US9340590B2 (en) | 2016-05-17 |
EA201391331A1 (ru) | 2014-02-28 |
AR088413A1 (es) | 2014-06-11 |
WO2012125973A3 (en) | 2013-01-03 |
HK1198173A1 (en) | 2015-03-13 |
AP2013007173A0 (en) | 2013-10-31 |
NZ615242A (en) | 2016-03-31 |
ZA201306920B (en) | 2014-05-28 |
CR20130533A (es) | 2014-01-09 |
SG10201601789TA (en) | 2016-04-28 |
US9796766B2 (en) | 2017-10-24 |
US20160304570A1 (en) | 2016-10-20 |
JP2017031157A (ja) | 2017-02-09 |
PE20140593A1 (es) | 2014-05-10 |
CL2013002673A1 (es) | 2014-07-25 |
CN103930437A (zh) | 2014-07-16 |
EP2686340A2 (en) | 2014-01-22 |
JP2014509859A (ja) | 2014-04-24 |
CA2830065A1 (en) | 2012-09-20 |
SG193434A1 (en) | 2013-10-30 |
TW201300407A (zh) | 2013-01-01 |
BR112013023674A2 (pt) | 2016-12-13 |
CO6821886A2 (es) | 2013-12-31 |
AU2012228990A1 (en) | 2013-09-19 |
MX2013010497A (es) | 2013-12-16 |
WO2012125973A2 (en) | 2012-09-20 |
KR20140145947A (ko) | 2014-12-24 |
US20140073577A1 (en) | 2014-03-13 |
AU2012228990B2 (en) | 2017-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33959A (es) | INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7 | |
UY33925A (es) | Inhibidores tricíclicos de quinasas | |
UY34541A (es) | ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?. | |
TWD180147S (zh) | 淨水器 | |
UY33946A (es) | Derivados de c4-monometil triterpenoides y sus métodos de uso | |
UY34502A (es) | Arilos y heteroarilos bicíclicos inhibidores de los canales de sodio | |
UY33958A (es) | Inhibidores de la glucosilceramida sintasa | |
UY34559A (es) | Inhibidores de bromodominios | |
UY34254A (es) | Proteínas y péptidos modificados. | |
UY34822A (es) | Composiciones y métodos para silenciar la expresión genética | |
UY34387A (es) | Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización. | |
UY33930A (es) | Inhibidores novedosos de quinasas | |
UY34004A (es) | INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA | |
UY34374A (es) | Benzilindazoles sustituidos | |
UY34472A (es) | Derivados modificados de 4-fenil-piridina | |
UY34271A (es) | Anticuerpos anti-tie2 y usos de los mismos | |
UY34034A (es) | Triazolopiridinas | |
UY34636A (es) | Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso | |
UY34071A (es) | Micropartícula inyectable de liberación controlada | |
UY34006A (es) | Imidazopiridazinas | |
UY34124A (es) | Cerramiento y método para conformarlo | |
UY34115A (es) | Ensayo de la lisil oxidasa-like 2 y sus métodos de empleo | |
UY34211A (es) | ?métodos y composiciones para producir arroz resistente a inhibidores de accasa?. | |
UY34158A (es) | Composicion herbicida | |
UY33976A (es) | Derivados de pirazolo-pirimidina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20201019 |